Table 1.
Baseline Characteristics of Derivation and Validation Cohorts
| PATIENT CHARACTERISTICS | Derivation Cohort n=441 |
Validation Cohort n=1513 |
|---|---|---|
| Age (years), mean ± SD | 69 ± 14 | 56 ± 15 |
| Male Sex, n (%) | 317 (72) | 1000 (66) |
| Race, n (%) | ||
| White | 410 (93) | 1114 (74) |
| African American | 9 (2) | 330 (22) |
| Other | 22 (5) | 69 (4) |
| Body Mass Index (Kg/m2), mean ± SD | 29 ± 6 | 30 ± 7 |
| Systolic BP (mmHg), Mean ± SD | 115 ± 20 | 114 ± 20 |
| Ejection Fraction (%), mean ± SD | 26 ± 6 | 34 ± 17 |
| Ischemic Cardiomyopathy, n (%) | 250 (57) | 455 (30) |
| NYHA Functional Class III/IV, n (%) | 294 (67) | 558 (37) |
| Implantable Defibrillator, n (%) | 181 (44) | 636 (42) |
| Estimated GFR, mL/min/1.73m2 | 58 ± 25 | 84 ± 32 |
| SHFM Score, mean ± SD | 0.80 ± 0.9 | −0.07 ± 1.0 |
| LABORATORIES | ||
| BNP (pg/mL), median (IQR) | 547 (276,1146) | 171 (47,576) |
| Creatinine (mg/dL), median (IQR) | 1.3 (1.0, 1.6) | 0.9 (0.8,1.3) |
| Sodium (mEq/L), mean ± SD | 139 ± 3.7 | 139 ± 3.4 |
| Uric Acid (mg/dL), median (IQR) | 7.8 (5.9,9.8) | 7.0 (5.7,8.8) |
| MEDICATIONS (%) | ||
| ACE inhibitors or ARBs | 71 | 87 |
| Aldosterone Antagonists | 25 | 34 |
| Beta-Blockers | 81 | 88 |
| Digoxin | 41 | 39 |
| Diuretics | 76 | 78 |
| Statin | 53 | 50 |
Abbreviations; BNP, brain natriuretic peptide; BP, blood pressure; GFR, glomerular filtration rate; NYHA, New York Heart Association, SHFM, Seattle Heart Failure Model.